The role of IL‐28, IFN‐γ, and TNF‐α in predicting response to pegylated interferon/ribavirin in chronic HCV patients
Adult
Male
0301 basic medicine
Interleukins
Interferon-alpha
Alanine Transaminase
Hepacivirus
Hepatitis C, Chronic
Middle Aged
Immunohistochemistry
Recombinant Proteins
Statistics, Nonparametric
Polyethylene Glycols
3. Good health
Interferon-gamma
03 medical and health sciences
Ribavirin
Humans
Drug Therapy, Combination
Female
Aspartate Aminotransferases
Biomarkers
Retrospective Studies
DOI:
10.1111/apm.12301
Publication Date:
2014-08-06T14:45:59Z
AUTHORS (7)
ABSTRACT
The primary goal of HCV therapy is to achieve a sustained virological response (SVR). Many host and viral factors influence the treatment response. Cytokines play an important role in the defense against viral infections, where successful treatment of hepatitis C depends on a complex balance between pro‐ and anti‐inflammatory responses. In the present study, we investigated the relationship between the presence and percentage of some cytokines (IL‐28, IFN‐γ, and TNF‐α) regarding different clinicopathological parameters including response to therapy in chronic HCV patients using immunohistochemical technique. This study was carried out on 64 chronic HCV patients (34 responders and 30 non‐responders). Of cases, 54% showed IL‐28 expression, which was associated with low AST (p = 0.002) and low HAI score (p = 0.006). Of cases, 67 and 45% showed IFN‐γ and TNF‐α expression, respectively, where the median percentage of TNF‐α expression was higher in grade II spotty necrosis compared to grade I. Some inflammatory cytokines expressed by intrahepatic inflammatory cells in chronic HCV patients promote inflammation and injury (pro‐inflammatory) such as TNF‐α. Other cytokines aid in resolving inflammation and injury (anti‐inflammatory) such as IL‐28. The balance between these cytokines will determine the degree of inflammatory state. None of the investigated cytokines proved its clear cut role in affecting response to therapy, however, their levels varied between responders and non‐responders for further investigations to clarify.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (39)
CITATIONS (5)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....